ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.667,76
-0,31%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,00%
Euro vs US Dollar
1,08284
-0,24%
Bitcoin
69.970,30
-0,23%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. Oragenics Inc (OGEN)

  7. Oragenics Inc (OGEN) News

OGEN

Oragenics (OGEN)

Oragenics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:OGEN
DatumZeitQuelleÜberschriftSymbolFirma
22/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
22/05/202414h00GlobeNewswire Inc.Oragenics Appoints William “Frank” Peacock MD as Chief Clinical OfficerAMEX:OGENOragenics Inc
17/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
17/05/202414h00GlobeNewswire Inc.Oragenics, Inc. to Host Webinar Panel on Neurotrauma MedicineAMEX:OGENOragenics Inc
16/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
16/05/202414h00GlobeNewswire Inc.Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion TrialAMEX:OGENOragenics Inc
15/05/202419h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:OGENOragenics Inc
07/05/202414h14Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
07/05/202414h00GlobeNewswire Inc.Oragenics Partners with Avance Clinical for Phase II Concussion Trial in AustraliaAMEX:OGENOragenics Inc
19/04/202423h50Business WireOragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsAMEX:OGENOragenics Inc
01/04/202415h05Business WireOragenics, Inc. Files 10K and Provides Company UpdateAMEX:OGENOragenics Inc
18/03/202412h00Business WireOragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating ConcussionAMEX:OGENOragenics Inc
06/03/202422h24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsAMEX:OGENOragenics Inc
05/03/202413h45Business WireOragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionAMEX:OGENOragenics Inc
01/03/202422h04Business WireOragenics Announces Closing of Public OfferingAMEX:OGENOragenics Inc
29/02/202422h41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:OGENOragenics Inc
28/02/202415h03Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
28/02/202403h25Business WireOragenics Announces Pricing of Public OfferingAMEX:OGENOragenics Inc
27/02/202423h09Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesAMEX:OGENOragenics Inc
27/02/202423h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:OGENOragenics Inc
27/02/202422h33Business WireOragenics Announces Proposed Public OfferingAMEX:OGENOragenics Inc
13/02/202402h06Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipAMEX:OGENOragenics Inc
12/02/202422h45Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
12/02/202422h41Business WireOragenics, Inc. Announces Leadership TransitionAMEX:OGENOragenics Inc
07/02/202414h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
07/02/202414h00Business WireOragenics, Inc. Announces Expiration of Its Investment Banking Engagement AgreementAMEX:OGENOragenics Inc
05/02/202414h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
05/02/202414h00Business WireOragenics, Inc. Preparing for Phase II Clinical Trials to Treat ConcussionAMEX:OGENOragenics Inc
23/01/202423h34Business WireOragenics Announces Termination of At-The-Market Offering ProgramAMEX:OGENOragenics Inc
23/01/202423h18Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
 Showing the most relevant articles for your search:AMEX:OGEN

Kürzlich von Ihnen besucht

AMEX
XLF
Financial Select Sector
NYSE
KO
Coca Cola
TG
TUI1
Tui
TG
BAS
BASF
COIN
ETHUSD
Ethereum
COIN
BTCUSD
Bitcoin
TG
CBK
Commerzbank
USOTC
BNPQY
BNP Paribas (QX)
DBI
MDAX
MDAX
DBI
TDXP
Tec DAX
TG
BAYN
Bayer
NASDAQ
AAPL
Apple
NASDAQ
NVDA
NVIDIA
PM
XAUUSD
Gold vs US Dollar
USOTC
RHHBY
Roche (QX)
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten